Reach Us +44-1764-910199
Fatigue Improvement after Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Apropos of a Case | OMICS International | Abstract
ISSN: 2165-7386

Journal of Palliative Care & Medicine
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Fatigue Improvement after Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Apropos of a Case

Javier Munoz* and Philip Kuriakose

Department of Hematology and Oncology, Henry Ford Hospital, 2799 W, Grand Blvd, Detroit Michigan 48202, USA

Corresponding Author:
Javier Munoz
Department of Hematology and Oncology
Henry Ford Hospital, Hematology-Oncology
2799 West Grand Blvd, Detroit, MI 48202, USA
Tel: 713-792-3934 / 713-854-6211
Fax: 713-792-3983
E-mail: [email protected]

Received Date: May 02, 2012; Accepted Date: June 14, 2012; Published Date: June 18, 2012

Citation:Munoz J, Kuriakose P (2012) Fatigue Improvement after Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Apropos of a Case. J Palliative Care Med 2:118. doi:10.4172/2165-7386.1000118

Copyright: © 2012 Munoz J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


A 54-year-old male presented with shortness of breath and was diagnosed with pulmonary emboli. Laboratory studies revealed hemolytic anemia. Flow cytometry showed a prominent white blood cell clone without CD59 in 85% (NV 0-3.0) and red blood cells with 8.5% CD59 absence (NV 0-3.0) confirming a diagnosis of paroxysmal nocturnal hemoglobinuria. Eculizumab was started to decrease the possibility of a thrombotic recurrence, with incidentally, a marked subjective improvement of symptomatology, as fatigue, was seen. We reviewed current literature regarding the improvement in fatigue seen in patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab.


Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version